ClinicalTrials.gg
CompletedNCT01063829Updated Feb 13, 2018Results posted

Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

A Phase 2 interventional study of 60 mg AIC246 and 120 mg AIC246 in HCMV Reactivation or HCMV End-Organ Disease, sponsored by AiCuris Anti-infective Cures AG. Completed at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-13.

Sponsored by AiCuris Anti-infective Cures AG · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).

02

Conditions studied

  • HCMV Reactivation or HCMV End-Organ Disease

Keywords

  • HCMV
03

In context

Lead sponsor

AiCuris Anti-infective Cures AG is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Seropositive for HCMV IgG antibodies before transplantation
  • First allogeneic Human blood precursor cell (HBPC) transplantation performed for 1 of the following diagnoses: leukaemia, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorder
  • Evidence of post transplantation engraftment
  • Able to swallow tablets.

Exclusion criteria

Exclusion Criteria:

  • Previous anti-HCMV therapy after this allogeneic HBPC transplantation
  • Mismatched or cord blood transplant recipients
  • Current or history of end-organ HCMV disease
  • (GVHD)
  • Impaired liver function
  • Reduced renal function
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Dose regimen 1

    60 mg AIC246, one tablet per day

    Drug: 60 mg AIC246

  • Experimental
    Dose regimen 2

    120 mg AIC246, one tablet per day

    Drug: 120 mg AIC246

  • Experimental
    Dose regimen 3

    240 mg AIC246, one tablet per day

    Drug: 240 mg AIC246

  • Other
    Placebo

    Placebo arm

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With "HCMV Prophylaxis Failure"

    Time frame: 84 days

  2. Time to Onset of "HCMV Prophylaxis Failure"

    Time frame: 84 days

Secondary outcomes

  1. Number of Patients With Systemic Detectable HCMV Replication.

    Time frame: 84 days

07

Results

Posted Feb 13, 2018

Participant flow

Participant flow — Overall Study
MilestoneAIC246 (60 mg)AIC246 (120 mg)AIC246 (240 mg)Placebo
Started33313433
Completed17212412
Not completed16101021

Outcome measures

PrimaryNumber of Participants With "HCMV Prophylaxis Failure"
Time frame:
84 days
Reported as:
Count of participants · Participants
Number of Participants With "HCMV Prophylaxis Failure"
ParticipantsAIC246 (60 mg)AIC246 (120 mg)AIC246 (240 mg)Placebo
Number of Participants With "HCMV Prophylaxis Failure"16101021
Statistical analysis
  • AIC246 (240 mg) vs Placebo · Fisher Exact · p = 0.007
  • AIC246 (120 mg) vs Placebo · Fisher Exact · p = 0.014
  • AIC246 (60 mg) vs Placebo · Fisher Exact · p = 0.321
PrimaryTime to Onset of "HCMV Prophylaxis Failure"
Time frame:
84 days
Reported as:
Number · days
Time to Onset of "HCMV Prophylaxis Failure"
daysAIC246 (60 mg)AIC246 (120 mg)AIC246 (240 mg)Placebo
Time to Onset of "HCMV Prophylaxis Failure"76212
Statistical analysis
  • AIC246 (240 mg) vs Placebo · Log Rank · p = 0.002
  • AIC246 (120 mg) vs Placebo · Log Rank · p = 0.126
  • AIC246 (60 mg) vs Placebo · Log Rank · p = 0.148
SecondaryNumber of Patients With Systemic Detectable HCMV Replication.
Time frame:
84 days
Reported as:
Count of participants · Participants
Number of Patients With Systemic Detectable HCMV Replication.
ParticipantsAIC246 (60 mg)AIC246 (120 mg)AIC246 (240 mg)Placebo
Number of Patients With Systemic Detectable HCMV Replication.75212
Statistical analysis
  • AIC246 (240 mg) vs Placebo · Fisher Exact · p = 0.007
  • AIC246 (120 mg) vs Placebo · Fisher Exact · p = 0.014
  • AIC246 (60 mg) vs Placebo · Fisher Exact · p = 0.321

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIC246 (60 mg)2/33 (6.1%)13/33 (39.4%)31/33 (93.9%)
AIC246 (120 mg)1/31 (3.2%)15/31 (48.4%)29/31 (93.5%)
AIC246 (240 mg)1/34 (2.9%)12/34 (35.3%)34/34 (100%)
Placebo1/33 (3%)16/33 (48.5%)33/33 (100%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventAIC246 (60 mg)AIC246 (120 mg)AIC246 (240 mg)Placebo
Acute Graft Versus Host Disease in IntestineImmune system disorders4/330/312/342/33
PyrexiaGeneral disorders1/330/310/343/33
PneumoniaInfections and infestations2/332/312/340/33
Acute Myeloid LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/332/310/340/33
Cytomegalovirus InfectionInfections and infestations0/331/310/342/33
Febrile NeutropeniaBlood and lymphatic system disorders0/331/310/342/33
Spinal Compression FractureInjury, poisoning and procedural complications2/330/310/340/33
Transplant FailureInjury, poisoning and procedural complications2/330/310/340/33
LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/330/312/340/33
Enterococcal BacteraemiaInfections and infestations0/331/310/340/33
Most frequent other events
Showing 10 of 366
Most frequent other events
EventAIC246 (60 mg)AIC246 (120 mg)AIC246 (240 mg)Placebo
NauseaGastrointestinal disorders7/338/317/3411/33
Cytomegalovirus InfectionInfections and infestations6/336/315/3411/33
DiarrhoeaGastrointestinal disorders9/339/3111/3410/33
VomittingGastrointestinal disorders4/3310/318/344/33
FatigueGeneral disorders3/338/314/345/33
CoughRespiratory, thoracic and mediastinal disorders2/338/315/341/33
Oedema PeripheralGeneral disorders4/333/318/343/33
HeadacheNervous system disorders4/333/318/343/33
RashSkin and subcutaneous tissue disorders4/335/314/346/33
PyrexiaGeneral disorders3/334/315/346/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)AIC246 (60 mg)AIC246 (120 mg)AIC246 (240 mg)PlaceboTotal
Mean50.5 ± 13.0351.6 ± 12.7950.7 ± 11.7851.8 ± 13.4151.1 ± 12.62
Sex: Female, Male
Sex: Female, Male(Participants)AIC246 (60 mg)AIC246 (120 mg)AIC246 (240 mg)PlaceboTotal
Female199121454
Male1422221977
Region of Enrollment
Region of Enrollment(participants)AIC246 (60 mg)AIC246 (120 mg)AIC246 (240 mg)PlaceboTotal
United States1819171569
Germany1512171862
08

Study locations

24 sites
  • UCLA Medical Center
    Los Angeles, California, United States
  • Stanford University Hospital
    Stanford, California, United States
  • Denver St. Lukes Presbyterian
    Denver, Colorado, United States
  • University of Florida
    Gainesville, Florida, United States
  • University of Chicago Medical Center
    Chicago, Illinois, United States
  • Loyola University Chicago
    Maywood, Illinois, United States
  • Indiana BMT
    Beech Grove, Indiana, United States
  • University Of Iowa
    Iowa City, Iowa, United States
  • Dana Farber Cancer Institute,
    Boston, Massachusetts, United States
  • Karmanos Cancer Institute
    Detroit, Michigan, United States
  • University of Minnesota
    Minneapolis, Minnesota, United States
  • Jeanes Hospital of TUHS
    Philadelphia, Pennsylvania, United States
  • UPMC Cancer Center
    Pittsburgh, Pennsylvania, United States
  • MD Anderson Cancer Center
    Houston, Texas, United States
  • Universitaetsklinikum Dresden
    Dresden, Germany
  • Universitaetsklinikum Erlangen-PS
    Erlangen,, Germany
  • Universitätsklinikum Freiburg
    Freiburg, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, Germany
  • Universitaeetsklinikum Heidelberg, ,
    Heidelberg, Germany
  • Universitaetsklinikum Mainz
    Mainz, Germany
  • Universitaetsklinikum Muenster
    Muenster, Germany
  • Klinikum Nuernberg Nord
    Nuernberg, Germany
  • Robert-Bosch-Krankenhaus
    Stuttgart, Germany
  • Universitaetsklinikum Wuerzburg
    Würzburg, Germany
09

References and documents

Publications

  • Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhauser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kolling K, Stobernack HP, Lischka P, Zimmermann H, Rubsamen-Schaeff H, Champlin RE, Ehninger G; AIC246 Study Team. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014 May 8;370(19):1781-9. doi: 10.1056/NEJMoa1309533. PubMed 24806159 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2018, 6 years 4 months after primary completion. A results delay was requested in Jan 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2010
First posted
Feb 5, 2010
Start
Mar 2010
Primary completionActual
Oct 2011
CompletionActual
Dec 2011
Results delay requested
Jan 24, 2013
Results first posted
Feb 13, 2018
Last update
Feb 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01063829
Lead sponsor
AiCuris Anti-infective Cures AG
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Feb 5, 2010
Start date
Mar 2010
Primary completion
Oct 2011
Completion
Dec 2011
Results posted
Feb 13, 2018
Last update
Feb 13, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion